Axogen Q4: EPS Miss Amid Biologics Transition

2026-02-25 05:23:33 ET

Thesis

Axogen, Inc. ( AXGN ) has just reported a 4Q25 non-GAAP EPS of $0.07, a figure which missed expectations by about $0.03. Elsewhere, revenue came in at $59.9 million, in line with estimates, growing 21.3% year over year. Management has expectations for at least 18% revenue growth in 2026, which would imply about $265.7 million in sales, a figure just above consensus. Gross margin is projected between 74% and 76%, and full-year free cash flow positivity, which is a nice sign. But as you know, despite the constructive outlook, investors were more focused on the earnings miss, and shares closed about 8% lower yesterday. I think the main concern is over near-term profitability and margin pressures....

Read the full article on Seeking Alpha

For further details see: